- Home
- ZION vs DVA Comparison
ZION vs DVA Comparison
Compare ZION & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | DVA |
|---|---|---|
| Founded | 1873 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.2B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ZION | DVA |
|---|---|---|
| Price | $58.57 | $113.56 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 19 | 4 |
| Target Price | $60.74 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 1.5M | 724.6K |
| Earning Date | 01-20-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 27.47 | 5.63 |
| EPS | 5.59 | ★ 9.76 |
| Revenue | $3,207,000,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $12.03 | $6.50 |
| Revenue Next Year | $4.35 | $2.97 |
| P/E Ratio | ★ $10.50 | $11.66 |
| Revenue Growth | ★ 6.54 | 5.14 |
| 52 Week Low | $39.32 | $112.54 |
| 52 Week High | $60.77 | $179.60 |
Technical Indicators
Market Signals| Indicator | ZION | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 35.64 |
| Support Level | $59.01 | $112.54 |
| Resistance Level | $59.66 | $114.34 |
| Average True Range (ATR) | 1.06 | 2.27 |
| MACD | -0.24 | -0.28 |
| Stochastic Oscillator | 14.44 | 7.15 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional US bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions focuses primarily on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.